Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
175 hedge funds and large institutions have $1.23B invested in Acorda Therapeutics in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 86 increasing their positions, 47 reducing their positions, and 34 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
83% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 47
1% less capital invested
Capital invested by funds: $1.25B → $1.23B (-$12M)
10% less funds holding
Funds holding: 194 → 175 (-19)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
87% less call options, than puts
Call options by funds: $2.53M | Put options by funds: $19.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$19.1M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$17.1M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.8M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$13.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.2M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.7M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$9.18M |
ACOR Hedge Fund Activity: Q2 2016 in Review
175 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2016, worth a combined $1.23B — down 0.96% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ACOR and 16 opened new positions — a net loss of 18 holders — while 47 trimmed existing stakes and 86 added.
The largest buyer was Fidelity Investments, adding an estimated $23.5M. The largest seller was Wellington Management Group, cutting an estimated $26.8M.
- 175 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2016, down from 194 in Q1 2016.
- Funds reported $1.23B of Acorda Therapeutics stock for Q2 2016, down 0.96% quarter-over-quarter.
- 16 funds opened new Acorda Therapeutics positions in Q2 2016 and 34 closed out, a net change of -18 holders.
- The largest Acorda Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $23.5M added.
- The largest Acorda Therapeutics seller in Q2 2016 was Wellington Management Group, an estimated $26.8M sold.
Based on aggregated 13F filings for Q2 2016.